Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Recurrence

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Antineoplastic Agents

All Drugs and Chemicals

Methyltestosterone

Hormones

Follicle Stimulating Hormone

Testosterone

Testosterone undecanoate

Testosterone enanthate

Testosterone 17 beta-cypionate

Hormone Antagonists

Androgens

Antineoplastic Agents, Hormonal

Anabolic Androgenic Steroids

Anabolic Agents

At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany) + recombinant FSH (Gonal-f, Merck Serrono S.A. Aubonne, Schweiz), 300 IU every second day for 5 weeks.

After 3 weeks: 1000 mg testosterone once.

At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany).

After 3 weeks: 1000 mg testosterone (Nebido, Bayer AB, Solna, Sweden) once.

Two doses of degarelix, 240 mg, subcutaneously once, at study start.

Degarelix 120 MG [Firmagon]

Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.

Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector

One dose 1000 mg testosterone once, after 3 weeks.

Testosterone Undecanoate

Yvonne Lundberg Giwercman, Professor

In order to elucidate if FSH can have testosterone like effects, samples from young, non-smoking healthy volunteers, with normal body mass index, and with pharmacologically induced gonadotropin deficiency will be studied regarding their capacity to induce prostate specific antigen (PSA), which normally is regulated by testosterone.

Normally, prostate specific antigen (PSA), which is a marker for prostate disease and progression, is exclusively produced in response to testosterone. In order to elucidate if follicle stimulating hormone (FSH) can have testosterone like effects, samples from n=30 non-smoking healthy volunteers, 20-30 years of age and with normal body mass index (20-25) with pharmacologically induced gonadotropin deficiency will be studied. The men are currently recruited and during 5 weeks undergoing:

1. Pharmacologically induced gonadotropin deficiency w 1-3;
2. FSH-treatment of 50% (group A), w 1-5;
3. Testosterone (T) treatment of all (group A and B) w 4-5;
4. End and follow up after 5 weeks.

A subcutaneous injection with the GnRH antagonist degarelix (240 mg¸ Ferring GmbH Wittland, Kiel, Germany) results in drop of both FSH and LH-induced testosterone. Half of the men will get recombinant FSH (300 IU; Gonal-f, Merck Serrono S.A. Aubonne, Schweiz) back, whereas 50% will not. Three weeks thereafter, the full spectrum of FSH dependent changes occur and are reflected in blood. From this occasion testosterone (Nebido, Ferring GmbH Wittland, Kiel, Germany) will be given to all participants to diminish the side-effects of the castration. Blood samples are collected at start, after 3 wks and after 5 wks. At that point also a follow up is undertaken. This experimental design will provide samples from each individual during normal conditions, during castration, and after a standardised dose of FSH.

Randomized case control study: one arm with FSH treatment for 5 weeks and one arm without FSH.

The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

Case Control Study Regarding the Role of Follicle Stimulating Hormone in Chemically Castrated Young Men

Swedish Cancer Foundation

ALF Swedish Government Grant

Lund University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer	NCT04134130	Prostate Cancer...	Degarelix 120 M... Gonal F RFF Pen... Testosterone Un...	20 Years - 30 Years	Lund University
The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer	NCT04134130	Prostate Cancer...	Degarelix 120 M... Gonal F RFF Pen... Testosterone Un...	20 Years - 30 Years	Lund University

Spots Global Cancer Trial Database for degarelix 120 mg [firmagon]